Skip to content
The BCI Briefing

FrontierWhat is becoming possible?

The BCI Frontier

A map of what brain-computer interfaces can do, arranged by how firmly each capability is established: demonstrated in people at the centre, emerging possibilities at the rim. Choose a domain to see what is possible today, the latest milestone, who is working on it and what has to happen next.

Today
Fig. 01 — The BCI FrontierSelect a domain. Dots are individual capabilities; hover for detail.
  • Demonstrated today
  • Early clinical
  • Research frontier
  • Emerging possibility

Zones are qualitative editorial judgements. A capability sits in a zone, not at a point, and the map implies no ranking between domains.

Frontier domain

Digital Autonomy

What is possible today

People with severe paralysis use implanted BCIs at home to message, browse and work, inside registered feasibility studies run in at least five countries.

Latest important milestone1 Oct 2026

Neuralink reported a cursor-control rate of 11.32 bits per second and weeks of use with minimal recalibration, after pretraining on pooled participant data.

Neuralink reports 11.32 bits per second after pretraining on pooled data

Capabilities by zone

Approaches
Intracortical cursor decoding · Endovascular switch control with eye tracking · Stable ECoG with adaptive decoders
Clinical maturity
Early feasibility across several commercial programmes. No pivotal trial is registered yet.
Labs
Massachusetts General HospitalStanford UniversityUniversity of California, San FranciscoRoyal Melbourne Hospital
Open datasets
FALCON benchmark
On the calendar
BCI Meeting 2027
Patent themes
903 patent families concern bci software and assistive and control applications. Filing shows where protection is sought, not that a capability works. The patent landscape

What needs to happen next

  1. 01A registered pivotal trial for a permanently implanted device
  2. 02Independent, peer-reviewed measurement of company-reported performance
  3. 03Shared outcome measures that capture independence, not only bit rate

This is where commercial activity is densest and where the first approval for a permanent BCI is most likely to come from. The technical question has shifted from whether it works to whether it keeps working without support.

Unresolved and emerging

Open Frontiers

The questions that decide what happens next. Each is read across six dimensions, so that scientific momentum, clinical need and capital can be seen side by side.

    • Early human evidence
    • High technical uncertainty

    Published human data extend to years for a few participants and designs. Each new electrode technology has to earn its own record.

    Start fromPlug-and-play control of a brain–computer interface through neural map stabilizationSampling representational plasticity of simple imagined movements across days enables long-term neuroprosthetic controlIntracortical

    Scientific momentum
    moderate
    Clinical need
    high
    Human evidence
    moderate
    Technical maturity
    low
    Competition density
    moderate
    Capital intensity
    high

Bars show low, moderate or high on each dimension. These are BCI Briefing judgements intended to make the landscape legible. They do not rank opportunities and are not investment advice.

The outlook

What happens next?

Four horizons, from now to beyond five years. Observed trajectories are on the left; plausible milestones, necessary breakthroughs and key uncertainties follow to the right.

Now

1–2 years

  • Plausible next milestone

    A pivotal trial of a permanently implanted BCI is registered.

    Synchron

  • Plausible next milestone

    Peer-reviewed results appear from commercial early feasibility studies.

    COMMANDConnect-One

  • Necessary breakthrough

    High-performance decoders that stay calibrated for months without supervised retraining.

    FALCON benchmark

  • Key uncertainty

    Whether signal quality from newer electrode designs holds beyond the first years in people.

3–5 years

  • Plausible next milestone

    A first marketing authorisation for an implanted communication or control BCI in a major market.

  • Necessary breakthrough

    Fully implanted, wireless, high-channel systems with multi-year reliability data.

  • Key uncertainty

    Reimbursement, surgical capacity and long-term device support — the factors that decided the pace of cochlear implant adoption.

    Hearing

Beyond

  • Plausible next milestone

    Bidirectional systems that combine movement and touch in everyday use.

    Somatosensory Feedback

  • Necessary breakthrough

    A non-implanted signal with bandwidth approaching implanted systems. There is no human evidence for this yet.

    Merge Labs

  • Key uncertainty

    How society chooses to govern interfaces for people without a medical need.

Only the first column describes what has happened. Everything to its right is a forward-looking judgement by The BCI Briefing as of 3 Oct 2026, and should be read as uncertain.